Patent ID: 9511114
Filing Date: 2016-12-06
CPC Classification: A61K,A61P,A61Q,C07K,C12N,C12Y,Y02A

Claim Text:
1. A composition comprising a modified Clostridium botulinum neurotoxin serotype E (BoNT/E) polypeptide exhibiting a reduced duration of muscle paralysis in a subject, wherein the modified BoNT/E polypeptide comprises at least one degradation signal in the light chain of a BoNT/E polypeptide, wherein the degradation signal in the light chain of the modified BoNT/E polypeptide is selected from: a) at least one internally or terminally introduced PEST motif; b) at least one internally or terminally introduced E3 ligase recognition motif; c) an N-terminal oligo-lysine residue; d) an N-terminally linked ubiquitin; e) a substitution of the N-terminal proline with a basic amino acid; f) substitutions of surface displayed amino acid residues with lysine; and g) a substitution of the N-terminal praline with a basic amino acid in combination with substitutions of surface displayed amino acid residues with lysine; and one or more pharmaceutically acceptable carriers.